HealingWell
Search Close Search
☰

Study - Adding Provenge to either Xtandi or Zytiga

Support Forums
>
Prostate Cancer
✚ New Topic ✚ Reply
❬ ❬ Previous Thread |Next Thread ❭ ❭
Posted 3/2/2020 11:50 PM (GMT 0)
I realize that Provenge isn’t the newest immunotherapy these days, but I believe it is still the only one approved for prostate cancer. Seems to be a very significant difference when added to Xtandi or Zytiga. I understand it’s probably a challenge to obtain the necessary insurance approvals, but if you could get Provenge while you’re taking these oral meds, why not?
——————————————————————————-
https://www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-press-releases/119338-asco-gu-real-world-study-finds-adding-immunotherapy-reduces-death-by-45-in-advanced-prostate-cancer.html

ASCO GU: Real World Study Finds Adding Immunotherapy Reduces Death by 45% in Advanced Prostate Cancer

San Francisco, CA (UroToday.com) -- Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, released results of a first-of-its-kind study examining survival outcomes in men with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with PROVENGE® (sipuleucel-T) and oral agents in a real-world treatment setting.

According to a retrospective analysis of medical and pharmacy claims data from more than 6,000 Medicare Fee for Service beneficiaries, the addition of PROVENGE to either Zytiga® (abiraterone acetate) or Xtandi® (enzalutamide), at any point in a patient’s mCRPC treatment regimen, reduced the risk of death by 45% and extended median overall survival (OS) by 14.5 months.1 These findings were presented in a poster session at the 2020 ASCO Genitourinary (GU) Cancers Symposium in San Francisco (abstract #42, Poster Session A, 11:30 a.m. PST).

“Based on our analysis of these real-world data, men with mCRPC who had immunotherapy added to their treatment regimen had a significant reduction in the risk of death at three years, regardless of the sequencing,” said Rana R. McKay, M.D., lead study author, and medical oncologist and assistant professor of medicine at Moores Cancer Center, University of California, San Diego. “This magnitude of risk reduction is a compelling finding, and additional analyses are underway looking at other variables that could impact outcomes.”

Based upon the real-world use and survival outcomes associated with the utilization of PROVENGE and oral agents Zytiga or Xtandi in men receiving treatment for mCRPC, the study authors found that:

In mCRPC patients treated with Zytiga or Xtandi, the median OS was significantly higher among men who also were treated with PROVENGE (35.2 months vs. 20.7 months; p<0.0001).

Three-year survival rates were significantly higher in men who received PROVENGE in any line of treatment compared to men who never received treatment with PROVENGE (48% vs. 28%; p<0.0001).

More than 150 variations of mCRPC treatment sequences were identified in the analysis, underscoring the importance of developing a structured approach to managing mCRPC patients. Further statistical analysis of these treatment cohorts is underway.

“These findings underscore the importance of using complementary MOAs to maximize patient survival outcomes, and highlights the critical role immunotherapy plays in the mCRPC treatment regimen,” said Bruce A. Brown, M.D., chief medical officer at Dendreon. “These real-world data contribute to a growing body of evidence that PROVENGE continues to deliver on its promise of helping men with advanced prostate cancer live longer.”
Posted 3/4/2020 10:44 PM (GMT 0)
Very interesting. Worth a discussion with the MO. Thanks for sharing...
Posted 3/4/2020 11:09 PM (GMT 0)
I notice that they seem to try everything on guys who are CR first. If they benefit, then it filters down to HS guys. This is probably how it ought to be - those fellas need it NOW. The thing that gripes me is they then do a four year trial on HS guys before the FDA approves the treatment for those who are HS. Early use of the second line ADT drugs are an example of this. It doesn't take a genius to figure out that if it benefits CR men it almost certainly will benefit HS guys.

Oh well, I'm sure there are legitimate reasons for the way things are done.
Posted 3/5/2020 8:15 PM (GMT 0)
My dear husband is headed in the Provenge direction along with the CHARRTED2 (Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel:
Posted 3/5/2020 8:28 PM (GMT 0)
This is the abstract. There is a link to the ASCO poster on the page.

Djin.
Posted 3/7/2020 12:01 AM (GMT 0)

When I was growing up, my grandfather was diagnosed with advanced prostate cancer, and there were no viable treatments available for him.

Many of the treatments that have helped many of us here have only become available within the past decade.

This website is a shining example of members who have described and documented their experiences with new treatments and medications.

I have gratitude, beyond words, for members and readers here who have also signed up for clinical trials.

Step by step, discoveries are made ... like a cobblestone path, leading us forward ...

Thankful for every new discovery,
Cyclone - Iowa State University
Posted 3/12/2020 4:13 AM (GMT 0)
Thanks for the post! As one on Zytiga with slowly rising PSA now at 1.5 I’ll ask my onco teams. Thanks!
Posted 3/12/2020 11:38 PM (GMT 0)
This result looks quite promising, but it must be pointed out that this wasn't a double-blind or single-blind study. I hope that the result will hold up once published in a peer-reviewed journal.

Post Edited (Sr Sailor) : 3/12/2020 5:43:48 PM (GMT-6)

Posted 3/13/2020 12:09 AM (GMT 0)
Todd1963 is testament to what Provenge can do. My urology practice gets high risk men into Provenge at the earliest possible time, because they know it works. They have several hundred men on. We know it doesn’t treat or cure, but it softens the PCa so the next treatment works much better.
Posted 3/13/2020 3:06 AM (GMT 0)

Sr Sailor said...
This result looks quite promising, but it must be pointed out that this wasn't a double-blind or single-blind study. I hope that the result will hold up once published in a peer-reviewed journal.

Phase III studies are often not blinded: they are comparing something new to a standard treatment and not to a placebo. For metastatic cancers the RECIST solid tumor criteria are often used and provide rather clear cut, objective results based on met measurements in CT scans, which are also checked for new lesions. The scans of patients who progress (a new lesion or increased size of target lesions over a certain percentage as determined at the trial Site) are usually submitted to, and re-read by, a central radiology lab for confirmation.

And a randomized trial, also preferable, would have to be much more limited than the study done, which claims yo have looked at about 150 treatment treatment sequencing variations.

The above study was retrospective, not prospective, and based on 3-year survival, so it's a different kind of study.

Djin

Post Edited (DjinTonic) : 3/13/2020 4:49:20 AM (GMT-6)

✚ New Topic ✚ Reply